KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Equity (2016 - 2025)

Historic Return on Equity for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 0.29%.

  • CRISPR Therapeutics AG's Return on Equity fell 1500.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.21% for FY2024, which is 1200.0% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Return on Equity of 0.29% as of Q3 2025, which was down 1500.0% from 0.29% recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Return on Equity peaked at 0.2% during Q2 2021, and registered a low of 0.34% during Q4 2022.
  • For the 5-year period, CRISPR Therapeutics AG's Return on Equity averaged around 0.15%, with its median value being 0.21% (2024).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Return on Equity soared by 3900bps in 2021 and then crashed by -4900bps in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Return on Equity stood at 0.15% in 2021, then tumbled by -322bps to 0.34% in 2022, then skyrocketed by 70bps to 0.1% in 2023, then crashed by -106bps to 0.21% in 2024, then plummeted by -39bps to 0.29% in 2025.
  • Its Return on Equity stands at 0.29% for Q3 2025, versus 0.29% for Q2 2025 and 0.23% for Q1 2025.